نوع مقاله : مقاله پژوهشی
نویسندگان
1 گروه مهندسی پرتوپزشکی، واحد علوم و تحقیقات، دانشگاه آزاد اسلامی، تهران، ایران.
2 پژوهشکده کاربرد پرتوها، پژوهشگاه علوم و فنون هسته ای، تهران- ایران
3 پژوهشکده کاربرد پرتوها، پژوهشگاه علوم و فنون هسته ای، تهران-ایران
کلیدواژه‌ها
موضوعات
عنوان مقاله English
نویسندگان English
This study was conducted with the aim of developing an advanced theranostic system based on gadolinium-doped cadmium selenide nanoparticles, labeled with lutetium-177 ([¹⁷⁷Lu]Lu@Gd-CdSe). In the first stage, the nanoparticles were successfully synthesized and characterized, and the results revealed particles with an average size of approximately 3.5 nm and a cubic crystalline structure. Subsequently, 100 µL of these nanoparticles were radiolabeled with lutetium-177 under optimized conditions (temperature: 70°C, pH: 7, and duration: 60 minutes), achieving radiolabeling purity and yield greater than 99%. The results demonstrated that the radiolabeled compound exhibited significant stability in phosphate-buffered saline and in human serum. To evaluate the biodistribution, 7.4 MBq of the radiolabeled compound and free lutetium were injected into healthy mice via the tail vein. While the free lutetium showed notable accumulation in the bones and kidneys, the radiolabeled compound primarily accumulated in the liver, spleen, and lungs—mainly due to uptake by macrophages of the reticuloendothelial system. The very low bone accumulation of the radiolabeled compound indicates its high in vivo stability. These findings suggest that this novel system could be a promising candidate for targeted treatment of including hepatic tumors. This research represents a significant step forward in the advancement of nuclear medicine and integrated diagnostic-therapeutic (theranostic) approaches.
کلیدواژه‌ها English
